title: Protective immunization against Staphylococcus aureus infection in a novel experimental wound model in mice.
abstract: A novel murine experimental wound infection model was used to assess the efficacy of multi-component immunization against Staphylococcus aureus infection. Necrotic lesions were induced in mice with venom from Bothrops asper and infected with a low inoculum, 1 × 10(2) CFU. The wound infection model therefore more resembles a clinical case of S. aureus infection compared with conventional infection models where far more bacteria are required. Before infection, mice were immunized with four recombinant S.aureus proteins expressed from Escherichia coli: (i) domains 1-3 of Extracellular adherence protein (Eap), (ii) Efb - D (fusion protein combining Extracellular fibrinogen binding protein (Efb) and a fibronectin binding domain (D) of the fibronectin binding protein (FnBP) and (iii) clumping factor A (ClfA). In the immunized group, lower bacterial colonization, undisturbed crust formation and significantly faster wound healing were found compared with the unimmunized control group. Efb and Eap have previously been found to impair wound healing and neutralization of these proteins by antibodies restores a more natural wound healing process. This effect is further also enhanced by the proposed opsonic activity of antibodies against ClfA and FnBP.
authors.affiliation: Department of Molecular Medicine and Surgery, Section of Reconstructive Plastic Surgery, Karolinska Institutet, Stockholm, Sweden. torgny.schennings@ki.se
authors.forename: Torgny
authors.initials: T
authors.lastname: Schennings
authors.forename: Filip
authors.initials: F
authors.lastname: Farnebo
authors.forename: Laszlo
authors.initials: L
authors.lastname: Szekely
authors.forename: Jan-Ingmar
authors.initials: JI
authors.lastname: Flock
mesh_terms: D018829:Adhesins, Bacterial / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D017837:Bothrops; D003030:Coagulase / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D003435:Crotalid Venoms / Q000008:administration & dosage*; D004926:Escherichia coli; D005260:Female; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D009336:Necrosis / Q000276:immunology / Q000473:pathology; D016601:RNA-Binding Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D013203:Staphylococcal Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology*; D014946:Wound Infection / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; C515944:ClfA protein, Staphylococcus aureus; D003030:Coagulase; D003435:Crotalid Venoms; C444739:Eap-N protein, Staphylococcus aureus; C114014:Efb protein, Staphylococcus aureus; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; D013209:Staphylococcal Vaccines; C078635:fibronectin-binding proteins, bacterial